NIBR-0213
CAS No. 1233332-14-3
NIBR-0213( NIBR 0213 | NIBR0213 )
Catalog No. M27904 CAS No. 1233332-14-3
NIBR-0213, a potent and selective S1P(1) antagonist, has efficacy in experimental autoimmune encephalomyelitis.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
2MG | 49 | Get Quote |
|
5MG | 69 | Get Quote |
|
10MG | 102 | Get Quote |
|
25MG | 206 | Get Quote |
|
100MG | Get Quote | Get Quote |
|
200MG | Get Quote | Get Quote |
|
500MG | Get Quote | Get Quote |
|
1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameNIBR-0213
-
NoteResearch use only, not for human use.
-
Brief DescriptionNIBR-0213, a potent and selective S1P(1) antagonist, has efficacy in experimental autoimmune encephalomyelitis.
-
DescriptionNIBR-0213, a potent and selective S1P(1) antagonist, has efficacy in experimental autoimmune encephalomyelitis.(In Vitro):In Ca2+?mobilization assays, NIBR-0213 displayed an inhibitory activity on hS1P1?with an IC50?of 2.5?nM whereas it was inactive (IC50?> 10?μM) on S1P2, S1P3, and S1P4. In GTPγ35S assays, NIBR-0213 displayed potent and comparable potency on human and rat S1P1?(IC50?of 2.0?nM and 2.3?nM, respectively), whereas on mouse S1P1?a slightly reduced IC50?of 8.5?nM was?measured. NIBR-0213 showed an ~3,000-fold selectivity against human S1P5?in the GTPγ35S assay (Figure?3A). On S1P4, a weak agonistic activity was detected with an EC50?of 245?nM. Schild plot analysis indicated that NIBR-0213 is a competitive S1P1?antagonist with a calculated Kd?of 0.37?± 0.031?nM.(In Vivo):NIBR-0213 increased in a dose-dependent manner the leakage of?plasma proteins?into lung parenchyma, as measured by the increase in EBD in lung tissues at 6?hr posttreatment (time of Emax on PBL). A maximum of 4–5-fold EBD increase versus vehicle controls was observed with 0.3?mg/kg. An ED50?of ~0.1?mg/kg could be estimated, i.e., in the range of the ED50?for the effects on PBL counts. NIBR-0213 given orally at 30 mg/kg to rats reduced the PBL counts by 75%–85% within 14 hr and maintained this effect up to 24 hr posttreatment.
-
In VitroNIBR-0213 displays an inhibitory activity on hS1P1?with an IC50?of 2.5?nM whereas it is inactive (IC50?>10?μM) on S1P2, S1P3, and S1P4?in Ca2+?mobilization assays.NIBR-0213 displays potent and comparable potency on human and rat S1P1?(IC50?of 2.0?nM and 2.3?nM, respectively) in GTPγ35S assays, whereas on mouse S1P1?with an IC50?of 8.5?nM.NIBR-0213 shows an ~3,000-fold selectivity against human S1P5?in the GTPγ35S assay. NIBR-0213 is a competitive S1P1?antagonist with a calculated Kd?of 0.37±0.031?nM.
-
In VivoNIBR-0213 (given orally at 30?mg/kg to rats) reduces the peripheral blood lymphocyte?(PBL) counts by 75%-85% within 14?hr and maintained this effect up to 24?hr posttreatment.NIBR-0213 (30?mg/kg and 60?mg/kg) is efficacious when given therapeutically in a mouse experimental autoimmune encephalomyelitis (EAE) model.The PK properties of NIBR-0213 shows a moderate clearance (26?mL/min/kg) and a high oral bioavailability (69%), leading to significant exposure after oral dosing. Animal Model:Lewis or Wistar rats (220-250 g, males)Dosage:30?mg/kg Administration:Orally Result:Reduced the PBL counts by 75%-85% within 14?hr and maintained this effect up to 24?hr posttreatment.Animal Model:C57BL/6 mice bearing EAE model Dosage:30?mg/kg and 60?mg/kg Administration:30?mg/kg twice per day (BID) for 3?days and then increased to 60?mg/kg BID until the remainder of the experiment. In total, the treatment lasted 26?days Result:Resulted in a gradual reduction in disease-scores, with a divergence from vehicle controls that became significant after 5?days.
-
SynonymsNIBR 0213 | NIBR0213
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1233332-14-3
-
Formula Weight464.99
-
Molecular FormulaC27H29ClN2O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC[C@H](NC(=O)c1c(C)cc(cc1C)-c1cccc(N[C@H](C)c2ccc(Cl)c(C)c2)c1)C(O)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Harroun SG, et al. Biomarkers of cigarette smoking and DNA methylating agents: Raman, SERS and DFT study of 3-methyladenine and 7-methyladenine. Spectrochim Acta A Mol Biomol Spectrosc. 2017 Apr 5;176:1-7.
molnova catalog
related products
-
Scabertopin
Scabertopin has a significant antitumor effect in vitro in a concentration-dependent manner. It is isolated from the whole plant of Elephantopus scaber.
-
26RFa
Hypothalamic RFamide-related neuropeptide. Acts as a natural ligand of the orphan receptor GPR103. Exhibits orexigenic acitivity in mice upon central administration.
-
MS049 2HCl
MS049 is a potent and selective inhibitor of PRMT4 (IC50 = 34 nM) and PRMT6 (IC50 = 43 nM).